Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 6/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29619129 | 0.93 | BRD4 (0.36) | HTR2AHTR2CCREBBPCHRNB2CHRNA4 | |
| SCHEMBL31677722 | 0.90 | HTR2A (0.36) | HTR2AHTR2CMAP2K1CHRNB2CHRNA4 | |
| SCHEMBL29619087 | 0.88 | NPC1 (0.43) | HTR2ACREBBPCHRNB2CHRNA4 | |
| SCHEMBL29619093 | 0.86 | CHRNB2 (0.36) | HTR2AHTR2CCREBBPCHRNB2CHRNA4 | |
| SCHEMBL29619068 | 0.85 | MET (0.42) | HTR2ACREBBP | |
| SCHEMBL29619132 | 0.83 | TAS2R8 (0.43) | CREBBPCHRNB2CHRNA4 | |
| SCHEMBL29619088 | 0.83 | RAB9A (0.42) | HTR2ASLC6A2CREBBPCHRNB2CHRNA4 | |
| SCHEMBL31199048 | 0.83 | LMNA (0.41) | HTR2ASLC6A2CREBBPCHRNB2CHRNA4 | |
| SCHEMBL29619172 | 0.82 | HTT (0.37) | CREBBPCHRNB2CHRNA4 | |
| SCHEMBL29619020 | 0.82 | HTR2A (0.50) | HTR2AHTR2CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4236942-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022093850-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | HTR2A, HTR5A, HTR1A | HTR2A 1/4885SLC6A2 21/4885HTR2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.